MesotheliomaDR logo

24/7 Patient Assistance: 760-405-8205

Brian Hill, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

CLEVELAND CLINIC HOSPITAL

specialties & services

Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Targeted Therapy

  • Bio & Insurance Information

    Dr. Brian Hill is a medical oncologist from Cleveland,Ohio and he works at several hospitals in the area, such as Cleveland Clinic. He did his Medical Schooling from University of Chicago Pritzker School of Medicine and Residency in Internal Medicine from University of Chicago. The doctor is certified in Internal Medicine, Hematology & Medical Oncology from American Board of Internal Medicine and has an experience of more than 19 years.

    Insurance Accepted

    Aetna Choice POS IIAetna HMOFirst Health PPO

  • Education & Training

    dept_icon

    University of Chicago Pritzker School of Medicine

    Medical School

    dept_icon

    University of Chicago

    Residency

    dept_icon

    Cleveland Clinic Foundation

    Fellowship

  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Hematology

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    CLEVELAND CLINIC HOSPITAL

    Languages: English/Spanish

    (216) 445-0150

    9500 Euclid Ave Taussig Cancer Institute

    Cleveland, OH 44195

    Read More
  • Publications & Memberships

    Dr. Brian Hill has contributed to 3 publications.

    A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.

    Winter, A. M.,Landsburg, D. J.,Mato, A. R.,Isaac, K.,Hernandez-Ilizaliturri, F. J.,Reddy, N.,Smith, S.,Shadman, M.,Smith, M. R.,Caimi, P.,Jagadeesh, D.,Hill, B. T.; Blood. 2017 Aug 11.

    See more >>

    Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

    Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt...; Br. J. Haematol.. 2016-12-15.

    See more >>

    Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

    Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales M, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Cas...; Biol. Blood Marrow Transplant.. 2016-12-01.

    See more >>